tepotinib
merck
['nsclc', 'tepotinib', 'sclc']
just published in this large nonrandomized clinical trial of patients with met exon 14 skipping nsclc supports global approvals of tepotinib, enabling clinicians to implement optimal therapeutic approaches. #asco23 
JAMA is an international peer-reviewed general medical journal published weekly online and in print, and a member of the @JAMANetwork family of journals.